Roberto M. Franco , Carolina Soares , Ana Oliveira , Rui Vaz , Maria J. Rosas
{"title":"Rethinking age barriers in Parkinson’s disease for deep brain stimulation","authors":"Roberto M. Franco , Carolina Soares , Ana Oliveira , Rui Vaz , Maria J. Rosas","doi":"10.1016/j.neuchi.2025.101665","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The age cutoff for subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD) has been a contentious issue. Typically, it is offered to patients younger than 70 years. This study, however, aims to compare DBS efficacy outcomes between patients with age ≥70 years and those aged <70 years, potentially paving the way for a more inclusive approach to DBS in PD treatment.</div></div><div><h3>Methods</h3><div>This study is a retrospective, cross-sectional cohort study of PD patients who underwent STN-DBS between 2002 and 2019. The analysis included a comprehensive range of sociodemographic and clinical variables. The primary outcome was the reduction in Movement Disorder Society - Unified Parkinson's Disease Rating Scale part III (MDS-UDPRSIII). The secondary outcome was reduced levodopa equivalent daily dose (LEDD). The statistical analysis was performed in SPSS-25, with a stringent threshold of <em>p</em> < 0.05, to reject the null hypothesis, ensuring the robustness of our findings.</div></div><div><h3>Results</h3><div>From a cohort of 360 patients with PD who underwent STN-DBS, we included 15 patients 70 years or older with a mean age of 70.4 ± 0.9 years, a mean disease duration of 13.0 ± 2.8 years, and 61 patients younger than 70 years old with a mean age of 61.2 ± 6.6 years; median disease duration of 13.0 [IQR:10.0]. No significant statistical differences were found in the MDS-UPDRS-III score on both groups at the at baseline (<em>p</em> = 0.480), at one year (<em>p</em> = 0.341) and at three years of follow-up (<em>p</em> = 0.117). In both groups, postoperative reduction of LEDD was similar (35.7 [IQR: 33.91] vs 31.6 ± 18.3); (<em>p</em> = 0.960) in patients with age 70 years or older and those younger than 70 years respectively; nevertheless, patients with 70 years or older had higher LEDD at three years (<em>p</em> < 0.001).</div></div><div><h3>Conclusion</h3><div>Our study found no significant differences in the MDS-UPDRS-III in groups younger and older than 70 at baseline, at one year and at three years of follow-up. However, higher LEDD was necessary in the elderly group. This highlights the urgent need for more inclusive research to better understand the cost-effectiveness of DBS in this population. By conducting such research, we can ensure that all PD patients, regardless of age, have access to the most effective treatments.</div></div>","PeriodicalId":51141,"journal":{"name":"Neurochirurgie","volume":"71 3","pages":"Article 101665"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurochirurgie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0028377025000384","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
The age cutoff for subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD) has been a contentious issue. Typically, it is offered to patients younger than 70 years. This study, however, aims to compare DBS efficacy outcomes between patients with age ≥70 years and those aged <70 years, potentially paving the way for a more inclusive approach to DBS in PD treatment.
Methods
This study is a retrospective, cross-sectional cohort study of PD patients who underwent STN-DBS between 2002 and 2019. The analysis included a comprehensive range of sociodemographic and clinical variables. The primary outcome was the reduction in Movement Disorder Society - Unified Parkinson's Disease Rating Scale part III (MDS-UDPRSIII). The secondary outcome was reduced levodopa equivalent daily dose (LEDD). The statistical analysis was performed in SPSS-25, with a stringent threshold of p < 0.05, to reject the null hypothesis, ensuring the robustness of our findings.
Results
From a cohort of 360 patients with PD who underwent STN-DBS, we included 15 patients 70 years or older with a mean age of 70.4 ± 0.9 years, a mean disease duration of 13.0 ± 2.8 years, and 61 patients younger than 70 years old with a mean age of 61.2 ± 6.6 years; median disease duration of 13.0 [IQR:10.0]. No significant statistical differences were found in the MDS-UPDRS-III score on both groups at the at baseline (p = 0.480), at one year (p = 0.341) and at three years of follow-up (p = 0.117). In both groups, postoperative reduction of LEDD was similar (35.7 [IQR: 33.91] vs 31.6 ± 18.3); (p = 0.960) in patients with age 70 years or older and those younger than 70 years respectively; nevertheless, patients with 70 years or older had higher LEDD at three years (p < 0.001).
Conclusion
Our study found no significant differences in the MDS-UPDRS-III in groups younger and older than 70 at baseline, at one year and at three years of follow-up. However, higher LEDD was necessary in the elderly group. This highlights the urgent need for more inclusive research to better understand the cost-effectiveness of DBS in this population. By conducting such research, we can ensure that all PD patients, regardless of age, have access to the most effective treatments.
期刊介绍:
Neurochirurgie publishes articles on treatment, teaching and research, neurosurgery training and the professional aspects of our discipline, and also the history and progress of neurosurgery. It focuses on pathologies of the head, spine and central and peripheral nervous systems and their vascularization. All aspects of the specialty are dealt with: trauma, tumor, degenerative disease, infection, vascular pathology, and radiosurgery, and pediatrics. Transversal studies are also welcome: neuroanatomy, neurophysiology, neurology, neuropediatrics, psychiatry, neuropsychology, physical medicine and neurologic rehabilitation, neuro-anesthesia, neurologic intensive care, neuroradiology, functional exploration, neuropathology, neuro-ophthalmology, otoneurology, maxillofacial surgery, neuro-endocrinology and spine surgery. Technical and methodological aspects are also taken onboard: diagnostic and therapeutic techniques, methods for assessing results, epidemiology, surgical, interventional and radiological techniques, simulations and pathophysiological hypotheses, and educational tools. The editorial board may refuse submissions that fail to meet the journal''s aims and scope; such studies will not be peer-reviewed, and the editor in chief will promptly inform the corresponding author, so as not to delay submission to a more suitable journal.
With a view to attracting an international audience of both readers and writers, Neurochirurgie especially welcomes articles in English, and gives priority to original studies. Other kinds of article - reviews, case reports, technical notes and meta-analyses - are equally published.
Every year, a special edition is dedicated to the topic selected by the French Society of Neurosurgery for its annual report.